Wedmont Private Capital Purchases 592 Shares of Eli Lilly and Company (NYSE:LLY)

Wedmont Private Capital boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 4.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 13,002 shares of the company’s stock after buying an additional 592 shares during the period. Eli Lilly and Company accounts for approximately 0.7% of Wedmont Private Capital’s holdings, making the stock its 28th biggest position. Wedmont Private Capital’s holdings in Eli Lilly and Company were worth $11,681,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Marcum Wealth LLC lifted its stake in Eli Lilly and Company by 8.5% in the 3rd quarter. Marcum Wealth LLC now owns 3,144 shares of the company’s stock worth $2,785,000 after purchasing an additional 247 shares in the last quarter. Abner Herrman & Brock LLC boosted its stake in Eli Lilly and Company by 0.4% during the third quarter. Abner Herrman & Brock LLC now owns 26,508 shares of the company’s stock valued at $23,484,000 after buying an additional 103 shares during the last quarter. CWM LLC grew its holdings in Eli Lilly and Company by 3.3% during the 3rd quarter. CWM LLC now owns 75,089 shares of the company’s stock valued at $66,524,000 after buying an additional 2,389 shares in the last quarter. West Financial Advisors LLC bought a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $58,000. Finally, Gunderson Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. Gunderson Capital Management Inc. now owns 22,497 shares of the company’s stock worth $19,931,000 after acquiring an additional 223 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $919.91 on Thursday. The business’s 50-day moving average is $904.41 and its two-hundred day moving average is $850.31. The firm has a market capitalization of $874.29 billion, a PE ratio of 135.48, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on LLY shares. Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Guggenheim upped their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.